Kiran Rao, MD
Gastroenterology · Sparta, NJNPI 1487801403
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,175 of the $55,533 with a category attached, or 92.2%. 17 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 45.8% of the total. Among gastroenterology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 149 payments — averaging $372.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$25K
- AbbVie$22K
- Ironwood Pharmaceuticals, Inc$7K
- Gilead$579
- Takeda Pharmaceuticals U.S.A., Inc.$153
- Phathom Pharmaceuticals, Inc.$123
- plus $452 from 11 others
Across 140 payments — averaging $9186.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.2M
- Bausch Health US, LLC$79K
- Caris MPI, Inc.$26K
- Amgen$13K
- Pfizer$11K
- Madrigal Pharmaceuticals$5K
What the payments were for
- Speaking & faculty fees$51,17592%
- Travel & lodging$5151%
- Food & beverage$3,8197%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 41 | $25,445 |
| AbbVie | 62 | $22,252 |
| Ironwood Pharmaceuticals, Inc | 7 | $6,528 |
| Gilead | 19 | $579 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $153 |
| Phathom Pharmaceuticals, Inc. | 1 | $123 |
| E.r. Squibb & Sons, L.L.C. | 1 | $120 |
| Boston Scientific | 2 | $83 |
| Redhill Biopharma Inc. | 1 | $63 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Amgen(2 entities) | 2 | $30 |
| Johnson & Johnson(2 entities) | 2 | $30 |
| Bristol Myers Squibb | 2 | $29 |
| Sanofi | 1 | $24 |
| Braintree Laboratories, Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Sobi, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,533 in reported general payments places this provider in the 95th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 138 | $117,237 |
| XifaxanRifaximin | 47 | $100,302 |
| Dexlansoprazole DrDexlansoprazole | 111 | $47,608 |
| CreonLipase/Protease/Amylase | 24 | $45,038 |
| TrulancePlecanatide | 33 | $23,437 |
| MotegrityPrucalopride Succinate | 26 | $16,829 |
| Mesalamine | 19 | $15,376 |
| MovantikNaloxegol Oxalate | 31 | $15,117 |
| Pantoprazole Sodium | 1,169 | $12,982 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 77 | $12,333 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 74 | $10,301 |
| Lansoprazole | 24 | $5,625 |
| Sucralfate | 155 | $4,546 |
| Ursodiol | 25 | $3,753 |
| NexiumEsomeprazole Magnesium | 12 | $3,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $22,252 | $162,275162 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $25,445 | $134,040154 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $153 | $16,82926 claims |
| Redhill Biopharma Inc.Movantik | $63 | $15,11731 claims |
| Braintree Laboratories, Inc.Sutab | $17 | $12,33377 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in Sparta
- Vinod RustgiNew Brunswick$431K
- Zamir BrelviNewark$391K
- Adam ElfantMount Laurel$385K
- Devjit NayarHoboken$258K
- Lea ChenNew Brunswick$185K
- Alexander PerelmanWest Orange$160K
- Barry KaufmanEgg Harbor Township$157K
- Anish ShethPrinceton$151K
- Ramesh GuptaFair Lawn$143K
- Sanket PatelVoorhees$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.